Skowronski Adrian, Habbe Kirsten Julia, Kontopoulou Kalliopi, Kohlhaas Markus, Fili Sofia
Department of Ophthalmology, St. Johannes Hospital Dortmund, Johannesstrasse 9-17, 44137, Dortmund, Germany.
Graefes Arch Clin Exp Ophthalmol. 2025 Jul 31. doi: 10.1007/s00417-025-06928-0.
To report the three-year clinical outcomes and safety profile of standalone PreserFlo MicroShunt implantation.
A single-center, retrospective study of 151 eyes from 109 patients with open-angle glaucoma who underwent standalone microshunt implantation between February 2019 and December 2020.
The mean IOP decreased significantly from 22.64 ± 8.79mmHg preoperatively to 12.76 ± 3.93mmHg three years postoperatively, with a mean IOP reduction of 43.6% (p = < 0.001). The need for IOP-lowering medication was significantly reduced from 2.64 ± 1.15 at baseline to 0.71 ± 1.12 after three years, representing a mean reduction of 73.1% (p = < 0.001). Three years post-implantation, 64.41% of eyes were free of glaucoma medication. Qualified and complete surgical success (IOP ≤ 21mmHg) was achieved in 77.6% and 42.3% of eyes, respectively, at three years. The most common complications were transient ocular hypotony (40.4%), choroidal detachment (13.25%), hyphema (11.92%). The vast majority of complications were self-limiting and did not pose a threat to vision. Open revision surgery was necessary in 14 eyes (9.27%). 7 eyes (4.63%) underwent further glaucoma surgery due to surgical failure. No statistically significant reduction in endothelial cell density (ECD) was observed 3 years after microshunt implantation (n = 13; p = 0.526).
PreserFlo MicroShunt implantation is an effective surgical technique for lowering intraocular pressure and reducing the need for antiglaucoma medication while maintaining a favorable safety profile. Its effect remains stable three years after surgery.
报告单独植入PreserFlo微型分流器的三年临床疗效和安全性。
一项单中心回顾性研究，纳入了2019年2月至2020年12月期间109例开角型青光眼患者的151只眼，这些患者接受了单独的微型分流器植入术。
平均眼压从术前的22.64±8.79mmHg显著降至术后三年的12.76±3.93mmHg，平均眼压降低了43.6%（p＜0.001）。降低眼压药物的使用需求从基线时的2.64±1.15显著降至三年后的0.71±1.12，平均降低了73.1%（p＜0.001）。植入三年后，64.41%的眼睛无需使用青光眼药物。三年时，分别有77.6%和42.3%的眼睛达到了合格且完全的手术成功（眼压≤21mmHg）。最常见的并发症是短暂性低眼压（40.4%）、脉络膜脱离（13.25%）、前房积血（11.92%）。绝大多数并发症是自限性的，对视力无威胁。14只眼（9.27%）需要进行开放性翻修手术。7只眼（4.63%）因手术失败接受了进一步的青光眼手术。微型分流器植入三年后，未观察到内皮细胞密度（ECD）有统计学意义的降低（n = 13；p = 0.526）。
PreserFlo微型分流器植入术是一种有效的手术技术，可降低眼压并减少抗青光眼药物的使用需求，同时保持良好的安全性。术后三年其效果仍稳定。
